Evidence map›Paper›PMID 42514947›Full record

ReviewPharmaceutics2026

Cold Plasma-Enabled Interface Engineering and In-Situ Functionalization of Printable Feedstocks in Additive Manufacturing: Mechanisms, Materials, and Applications.

Xhoi Xibri, Giuseppe F Racaniello, Brendan Gilmore, Nunzio Denora, Dimitrios A Lamprou

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xhoi XibriSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0009-0009-9123-0517
Giuseppe F RacanielloDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona Street 4, 70125 Bari, Italy.ORCID 0000-0002-7827-0663
Brendan GilmoreSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.
Nunzio DenoraDepartment of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, Orabona Street 4, 70125 Bari, Italy.ORCID 0000-0002-7756-7828
Dimitrios A LamprouSchool of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK.ORCID 0000-0002-8740-1661

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cold plasma (CP) has emerged as a multifunctional surface engineering technology capable of enabling precise, non-thermal modification of material interfaces, while additive manufacturing (AM) has transformed modern fabrication through a layer-by-layer model of personalized therapies. This review discusses potential interactions between cold plasma technologies and additive manufacturing processes for pharmaceutical and biomedical applications. CP has been investigated for surface modifications before and after manufacturing processes in several material science applications. Through controlled surface activation and plasma-induced chemistry, CP-assisted processes can enhance interlayer adhesion, surface wettability, antimicrobial activity, and bioactivity of AM-fabricated models, by generating reactive species and introducing functional groups into the surfaces of materials. The review also discusses engineering and regulatory challenges associated with plasma technologies in AM. Overall, CP represents a versatile surface modification technology whose interaction with materials used in AM deserves further investigation.

Indexed as

additive manufacturingcold plasmaCritical Process AttributesCritical Quality Attributesdrug delivery systemsinterface engineeringprocess validationQuality by Designsurface functionalization

Identifiers

PMID42514947
PMCPMC13415086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.